Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:FGENNASDAQ:GBIONASDAQ:INABNASDAQ:TPST On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeFGENFibroGen$5.16-12.2%$7.62$4.50▼$38.25$23.77M0.8379,281 shs110,153 shsGBIOGeneration Bio$0.36-5.8%$0.39$0.32▼$3.65$25.61M2.66337,979 shs1.11 million shsINABIN8bio$2.13-0.5%$4.25$2.06▼$29.97$6.47M0.1895,992 shs129,799 shsTPSTTempest Therapeutics$6.90+0.7%$6.98$5.35▼$35.23$25.23M-2175,926 shs143,925 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceFGENFibroGen-12.24%-33.20%-34.18%-38.66%-79.96%GBIOGeneration Bio-5.76%-7.93%-10.40%-30.23%-86.67%INABIN8bio-0.47%-16.14%-43.20%-69.51%-92.90%TPSTTempest Therapeutics+0.73%-7.63%+3.60%-34.48%-81.38%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationFGENFibroGen4.534 of 5 stars3.35.00.04.71.73.30.6GBIOGeneration Bio3.9266 of 5 stars3.55.00.00.02.83.31.3INABIN8bio3.8797 of 5 stars3.55.00.00.03.32.51.3TPSTTempest Therapeutics2.6709 of 5 stars3.35.00.00.02.70.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceFGENFibroGen 2.50Moderate Buy$250.004,744.96% UpsideGBIOGeneration Bio 3.00Buy$7.331,937.04% UpsideINABIN8bio 3.00Buy$180.008,350.70% UpsideTPSTTempest Therapeutics 2.50Moderate Buy$30.00334.78% UpsideCurrent Analyst Ratings BreakdownLatest INAB, GBIO, FGEN, and TPST Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/13/2025FGENFibroGenHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$250.00 ➝ $250.005/8/2025GBIOGeneration BioNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$8.00 ➝ $8.004/10/2025GBIOGeneration BioNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$8.00 ➝ $8.004/10/2025TPSTTempest TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Neutral$16.00 ➝ $16.004/10/2025TPSTTempest TherapeuticsScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSector Outperform ➝ Sector Perform$7.00 ➝ $9.004/1/2025FGENFibroGenWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Perform3/28/2025TPSTTempest TherapeuticsScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetSector Outperform ➝ Sector Outperform$169.00 ➝ $91.003/28/2025TPSTTempest TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$611.00 ➝ $208.00(Data available from 6/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookFGENFibroGen$29.62M0.70N/AN/A($50.89) per share-0.10GBIOGeneration Bio$19.89M1.21N/AN/A$1.29 per share0.28INABIN8bioN/AN/AN/AN/A$6.00 per shareN/ATPSTTempest TherapeuticsN/AN/AN/AN/A$5.66 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateFGENFibroGen-$47.58M-$0.10N/AN/AN/A-9.73%N/A-24.77%8/5/2025 (Estimated)GBIOGeneration Bio-$131.67M-$1.08N/AN/AN/A-292.92%-75.84%-30.40%8/6/2025 (Estimated)INABIN8bio-$30.44M-$13.57N/AN/AN/AN/A-218.85%-139.59%8/14/2025 (Estimated)TPSTTempest Therapeutics-$41.84M-$17.98N/AN/AN/AN/A-305.51%-119.74%8/6/2025 (Estimated)Latest INAB, GBIO, FGEN, and TPST EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025TPSTTempest Therapeutics-$3.71-$3.16+$0.55-$3.16N/AN/A5/12/2025Q1 2025FGENFibroGen$0.75-$4.00-$4.75$0.05$2.00 million$2.70 million5/8/2025Q1 2025INABIN8bio-$1.80-$2.10-$0.30-$0.07N/AN/A5/7/2025Q1 2025GBIOGeneration Bio-$0.25-$0.22+$0.03-$0.22$1.70 million$8.72 million3/27/2025Q4 2024TPSTTempest Therapeutics-$3.12-$4.03-$0.91-$0.31N/A$0.49 million3/19/2025Q4 2024GBIOGeneration Bio-$0.31-$0.32-$0.01-$0.32$2.92 million$4.19 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthFGENFibroGenN/AN/AN/AN/AN/AGBIOGeneration BioN/AN/AN/AN/AN/AINABIN8bioN/AN/AN/AN/AN/ATPSTTempest TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioFGENFibroGenN/A2.021.98GBIOGeneration BioN/A8.438.43INABIN8bio0.014.304.30TPSTTempest TherapeuticsN/A1.701.70Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipFGENFibroGen72.71%GBIOGeneration Bio95.22%INABIN8bio92.05%TPSTTempest Therapeutics22.52%Insider OwnershipCompanyInsider OwnershipFGENFibroGen3.07%GBIOGeneration Bio21.80%INABIN8bio15.50%TPSTTempest Therapeutics4.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableFGENFibroGen5704.04 million3.92 millionOptionableGBIOGeneration Bio15067.04 million52.42 millionOptionableINABIN8bio203.02 million2.55 millionNot OptionableTPSTTempest Therapeutics203.68 million3.51 millionOptionableINAB, GBIO, FGEN, and TPST HeadlinesRecent News About These CompaniesTempest announces $4.6 million registered direct offering of common stock; shares decline over 13%June 11, 2025 | msn.comTempest Therapeutics, Inc. Announces $4.6 Million Registered Direct Offering of Common StockJune 11, 2025 | quiverquant.comTempest Announces $4.6 Million Registered Direct Offering of Common StockJune 11, 2025 | globenewswire.comTempest Therapeutics Executives Sign Consulting Agreements, Company Explores Strategic AlternativesJune 7, 2025 | marketwatch.comTempest Therapeutics Shares Up, Executive Team Enters Into Consulting AgreementsJune 7, 2025 | marketwatch.comTPST Stock Up on EMA's Orphan Drug Tag for Liver Cancer TherapyJune 6, 2025 | zacks.comTempest Therapeutics stock rises on EMA Orphan Drug DesignationJune 5, 2025 | au.investing.comTempest Receives Orphan Drug Designation from the European Medicines Agency for Amezalpat for the Treatment of Patients with HCCJune 5, 2025 | globenewswire.comTempest Therapeutics: Tempest Reports First Quarter 2025 Financial Results and Provides Business UpdateMay 16, 2025 | finanznachrichten.deTempest Reports First Quarter 2025 Financial Results and Provides Business UpdateMay 13, 2025 | finance.yahoo.comTempest Reports First Quarter 2025 Financial Results and Provides Business UpdateMay 13, 2025 | globenewswire.comTempest Presents New Amezalpat MOA Data Reinforcing Its Potential as Novel Cancer Treatment at the 2025 AACR Annual MeetingApril 28, 2025 | globenewswire.comDual EP2/EP4 Antagonist Designated Orphan Drug for Familial Adenomatous PolyposisApril 25, 2025 | empr.comCash-strapped Bay Area biotech company lays off all but 5 employeesApril 24, 2025 | msn.comTempest Therapeutics: FDA Grants Orphan Drug Designation To TPST-1495April 23, 2025 | nasdaq.comTempest Therapeutics Receives FDA Orphan Drug Designation for TPST-1495 to Treat Familial Adenomatous PolyposisApril 23, 2025 | nasdaq.comTempest TherapeuticsApril 22, 2025 | thepharmaletter.comTempest Therapeutics stock rises on FDA Orphan Drug DesignationApril 21, 2025 | in.investing.comTempest lays off 80% of workforce to ride out cash crunchApril 21, 2025 | fiercebiotech.comTempest Therapeutics announces FDA granted ODD to TPST-1495April 21, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Defense Stocks That Will Profit From a Golden DomeBy Chris Markoch | May 30, 2025View 3 Defense Stocks That Will Profit From a Golden DomeAnalysts Think These Stocks Could More Than Double in ValueBy Nathan Reiff | May 23, 2025View Analysts Think These Stocks Could More Than Double in ValuePfizer's 7.5% Dividend: Income Haven or House of Cards?By Jeffrey Neal Johnson | May 23, 2025View Pfizer's 7.5% Dividend: Income Haven or House of Cards?Chime’s Smart IPO: Half the Valuation, Double the StrengthBy Jeffrey Neal Johnson | June 18, 2025View Chime’s Smart IPO: Half the Valuation, Double the StrengthRed Robin's Comeback: Q1 Earnings Spark Investor HopesBy Jeffrey Neal Johnson | June 5, 2025View Red Robin's Comeback: Q1 Earnings Spark Investor HopesINAB, GBIO, FGEN, and TPST Company DescriptionsFibroGen NASDAQ:FGEN$5.16 -0.72 (-12.24%) Closing price 06/18/2025 04:00 PM EasternExtended Trading$5.19 +0.03 (+0.58%) As of 06/18/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.Generation Bio NASDAQ:GBIO$0.36 -0.02 (-5.76%) Closing price 06/18/2025 04:00 PM EasternExtended Trading$0.36 +0.01 (+1.39%) As of 06/18/2025 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Generation Bio Co. develops non-viral genetic medicines for the treatment of rare and prevalent diseases. The company develops cell-targeted lipid nanoparticle (ctLNP) platform, a modular delivery system for nucleic acids to avoid off-target clearance by the liver and spleen that enables ctLNPs to persist in systemic circulation, which allows for highly selective and potent ligand-driven targeting to specific tissues and cell types; and novel immune-quiet DNA (iqDNA) to enable long-lasting high levels of gene expression from non-integrating episomes and avoids innate immune sensors that have long prevented DNA from use in non-viral systems. It uses its platform for developing a portfolio of programs for treating cancer, autoimmune, hematologic disorders, prioritizing sickle cell, beta-thalassemia, and hemophilia A diseases, as well as for other tissues and cell types, including retina, skeletal muscle, and central nervous system. The company was formerly known as Torus Therapeutics, Inc. and changed its name to Generation Bio Co. in November 2017. Generation Bio Co. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.IN8bio NASDAQ:INAB$2.13 -0.01 (-0.47%) Closing price 06/18/2025 04:00 PM EasternExtended Trading$2.17 +0.04 (+2.11%) As of 06/18/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.IN8bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidates include INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of glioblastoma and solid tumors; INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with acute leukemia undergoing hematopoietic stem cell transplantation; and INB-400, which is in Phase 2 clinical trial to treat newly diagnosed GBM. It also develops INB-300, INB-410, and INB-500 that are in preclinical Phase for treatment of various solid tumor cancers. The company was formerly known as Incysus Therapeutics, Inc. and changed its name to IN8bio, Inc. in August 2020. IN8bio, Inc. was incorporated in 2016 and is headquartered in New York, New York.Tempest Therapeutics NASDAQ:TPST$6.90 +0.05 (+0.73%) Closing price 06/18/2025 04:00 PM EasternExtended Trading$6.97 +0.07 (+1.01%) As of 06/18/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Tempest Therapeutics, Inc., a clinical-stage oncology company, develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various tumors. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, which is in a Phase 1 trial to treat cancer; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial for the treatment of solid tumors. It also develops TREX-1, an enzyme that regulates cGAS/STING pathway signaling and immune recognition. Tempest Therapeutics, Inc. was incorporated in 2011 and is headquartered in Brisbane, California. Tempest Therapeutics, Inc. operates as a subsidiary of Inception Sciences, Inc. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Chime’s Smart IPO: Half the Valuation, Double the Strength Salesforce Raises Prices: 3 Reasons Its Stock Price Will Follow Tesla Bulls and Bears Collide: What Investors Should Know Qualcomm: A Technical Setup Is Emerging, and It's Bullish 330% Returns YTD: Is CoreWeave's Momentum Softening? Why Quantum Computing Inc. Is the Quiet Winner in Quantum Stocks 3 Catalysts in 7 Days: Archer's Growth Story Just Accelerated Microsoft-OpenAI Rift May Cap Stock Upside Potential Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
